Cargando…

Ex Vivo Fluorescence Confocal Microscopy (FCM) Ensures Representative Tissue in Prostate Cancer Biobanking: A Feasibility Study

Background: Biobanking of prostate carcinoma is particularly challenging due to the actual cancer within the organ often without clear margins. Frozen sections are to date the only way to examine the biobank material for its tumor content. We used ex vivo fluorescence confocal microscopy (FCM) to an...

Descripción completa

Detalles Bibliográficos
Autores principales: Titze, Ulf, Sommerkamp, Johannes, Stege, Clara, Schneider, Fried, Brochhausen, Christoph, Schulz, Birte, Titze, Barbara, Abd Ali, Furat, Pokupic, Sasa, Sievert, Karl-Dietrich, Hansen, Torsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9603154/
https://www.ncbi.nlm.nih.gov/pubmed/36292970
http://dx.doi.org/10.3390/ijms232012103
_version_ 1784817477959548928
author Titze, Ulf
Sommerkamp, Johannes
Stege, Clara
Schneider, Fried
Brochhausen, Christoph
Schulz, Birte
Titze, Barbara
Abd Ali, Furat
Pokupic, Sasa
Sievert, Karl-Dietrich
Hansen, Torsten
author_facet Titze, Ulf
Sommerkamp, Johannes
Stege, Clara
Schneider, Fried
Brochhausen, Christoph
Schulz, Birte
Titze, Barbara
Abd Ali, Furat
Pokupic, Sasa
Sievert, Karl-Dietrich
Hansen, Torsten
author_sort Titze, Ulf
collection PubMed
description Background: Biobanking of prostate carcinoma is particularly challenging due to the actual cancer within the organ often without clear margins. Frozen sections are to date the only way to examine the biobank material for its tumor content. We used ex vivo fluorescence confocal microscopy (FCM) to analyze biobank samples prior to cryoasservation. Methods: 127 punch biopsies were acquired from prostatectomy-specimens from 40 patients. These biopsies were analyzed with a Vivascope 2500-G4 prior to their transfer to the biobank. In difficult cases, larger samples of the prostatectomy specimens were FCM scanned in order to locate tumor foci. After patient acquisition, all samples were taken from the biobank and analyzed. We compared the results of the FCM examinations with the results of conventional histology and measured the DNA content. Results: With upstream FCM, the tumor content of biobank samples could be determined with high confidence. The detection rate of representative biobank samples was increased due to the rapid feedback. The biobank samples were suitable for further molecular analysis. Conclusion: FCM allows for the first time lossless microscopic analysis of biobank samples prior to their cryoasservation and guarantees representative tumor and normal tissue for further molecular analysis.
format Online
Article
Text
id pubmed-9603154
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96031542022-10-27 Ex Vivo Fluorescence Confocal Microscopy (FCM) Ensures Representative Tissue in Prostate Cancer Biobanking: A Feasibility Study Titze, Ulf Sommerkamp, Johannes Stege, Clara Schneider, Fried Brochhausen, Christoph Schulz, Birte Titze, Barbara Abd Ali, Furat Pokupic, Sasa Sievert, Karl-Dietrich Hansen, Torsten Int J Mol Sci Article Background: Biobanking of prostate carcinoma is particularly challenging due to the actual cancer within the organ often without clear margins. Frozen sections are to date the only way to examine the biobank material for its tumor content. We used ex vivo fluorescence confocal microscopy (FCM) to analyze biobank samples prior to cryoasservation. Methods: 127 punch biopsies were acquired from prostatectomy-specimens from 40 patients. These biopsies were analyzed with a Vivascope 2500-G4 prior to their transfer to the biobank. In difficult cases, larger samples of the prostatectomy specimens were FCM scanned in order to locate tumor foci. After patient acquisition, all samples were taken from the biobank and analyzed. We compared the results of the FCM examinations with the results of conventional histology and measured the DNA content. Results: With upstream FCM, the tumor content of biobank samples could be determined with high confidence. The detection rate of representative biobank samples was increased due to the rapid feedback. The biobank samples were suitable for further molecular analysis. Conclusion: FCM allows for the first time lossless microscopic analysis of biobank samples prior to their cryoasservation and guarantees representative tumor and normal tissue for further molecular analysis. MDPI 2022-10-11 /pmc/articles/PMC9603154/ /pubmed/36292970 http://dx.doi.org/10.3390/ijms232012103 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Titze, Ulf
Sommerkamp, Johannes
Stege, Clara
Schneider, Fried
Brochhausen, Christoph
Schulz, Birte
Titze, Barbara
Abd Ali, Furat
Pokupic, Sasa
Sievert, Karl-Dietrich
Hansen, Torsten
Ex Vivo Fluorescence Confocal Microscopy (FCM) Ensures Representative Tissue in Prostate Cancer Biobanking: A Feasibility Study
title Ex Vivo Fluorescence Confocal Microscopy (FCM) Ensures Representative Tissue in Prostate Cancer Biobanking: A Feasibility Study
title_full Ex Vivo Fluorescence Confocal Microscopy (FCM) Ensures Representative Tissue in Prostate Cancer Biobanking: A Feasibility Study
title_fullStr Ex Vivo Fluorescence Confocal Microscopy (FCM) Ensures Representative Tissue in Prostate Cancer Biobanking: A Feasibility Study
title_full_unstemmed Ex Vivo Fluorescence Confocal Microscopy (FCM) Ensures Representative Tissue in Prostate Cancer Biobanking: A Feasibility Study
title_short Ex Vivo Fluorescence Confocal Microscopy (FCM) Ensures Representative Tissue in Prostate Cancer Biobanking: A Feasibility Study
title_sort ex vivo fluorescence confocal microscopy (fcm) ensures representative tissue in prostate cancer biobanking: a feasibility study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9603154/
https://www.ncbi.nlm.nih.gov/pubmed/36292970
http://dx.doi.org/10.3390/ijms232012103
work_keys_str_mv AT titzeulf exvivofluorescenceconfocalmicroscopyfcmensuresrepresentativetissueinprostatecancerbiobankingafeasibilitystudy
AT sommerkampjohannes exvivofluorescenceconfocalmicroscopyfcmensuresrepresentativetissueinprostatecancerbiobankingafeasibilitystudy
AT stegeclara exvivofluorescenceconfocalmicroscopyfcmensuresrepresentativetissueinprostatecancerbiobankingafeasibilitystudy
AT schneiderfried exvivofluorescenceconfocalmicroscopyfcmensuresrepresentativetissueinprostatecancerbiobankingafeasibilitystudy
AT brochhausenchristoph exvivofluorescenceconfocalmicroscopyfcmensuresrepresentativetissueinprostatecancerbiobankingafeasibilitystudy
AT schulzbirte exvivofluorescenceconfocalmicroscopyfcmensuresrepresentativetissueinprostatecancerbiobankingafeasibilitystudy
AT titzebarbara exvivofluorescenceconfocalmicroscopyfcmensuresrepresentativetissueinprostatecancerbiobankingafeasibilitystudy
AT abdalifurat exvivofluorescenceconfocalmicroscopyfcmensuresrepresentativetissueinprostatecancerbiobankingafeasibilitystudy
AT pokupicsasa exvivofluorescenceconfocalmicroscopyfcmensuresrepresentativetissueinprostatecancerbiobankingafeasibilitystudy
AT sievertkarldietrich exvivofluorescenceconfocalmicroscopyfcmensuresrepresentativetissueinprostatecancerbiobankingafeasibilitystudy
AT hansentorsten exvivofluorescenceconfocalmicroscopyfcmensuresrepresentativetissueinprostatecancerbiobankingafeasibilitystudy